Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.

PLoS One · 2021 · PMC8519417 · PMID 34653210

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, prophylactic therapy with SCIG increased serum IgG and specific antibody titers, was well tolerated, and showed a trend in decreased NNIs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.